92.22
+2.86(+3.20%)
Currency In USD
| Previous Close | 89.36 |
| Open | 89.16 |
| Day High | 92.48 |
| Day Low | 89.16 |
| 52-Week High | 92.48 |
| 52-Week Low | 49 |
| Volume | 128,497 |
| Average Volume | 53,759 |
| Market Cap | 3.01B |
| PE | -59.5 |
| EPS | -1.55 |
| Moving Average 50 Days | 72.36 |
| Moving Average 200 Days | 64.04 |
| Change | 2.86 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $8,708.22 as of October 24, 2025 at a share price of $92.22. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 2 years ago, it would be worth $2,436.46 as of October 24, 2025 at a share price of $92.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio to Participate in the 2025 Maxim Growth Summit
GlobeNewswire Inc.
Oct 16, 2025 12:00 PM GMT
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advanci
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
GlobeNewswire Inc.
Sep 12, 2025 12:00 PM GMT
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast subject visit